Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Rare Tumour 1Prostatic Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Carcinoma 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × envafolimab × Clear all
NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Chongqing University Cancer Hospital

Phase 2 Recruiting
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06055816 2023-09-28

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Zhejiang Cancer Hospital

Phase 2 Recruiting
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡